Your quality manufacturing processes are subject to planned and unplanned regulatory inspections with recently approved FDA budgets for surveillance activities to address the COVID-19 pandemic backlog.
This paper outlines what you should do to prepare, address and prevent 483’s and warning letters and how implementing the components of a culture of quality and leveraging technology, will equip you to answer questions and provide evidence at a moment’s notice.
